For the HAI procedure, a coaxial catheter (Renegade Hi Flo, Boston Scientific, Boston, MA, United States/Stride ASAHI INTECC, Seto, Japan) was inserted through the femoral artery using Seldinger’s technique. Based on the tumour location, a microcatheter was placed in the proper hepatic artery or the right or left hepatic arterial branch under arteriography guidance. The peripheral region of the microcatheter that was exposed outside the body was connected with an arterial chemotherapeutic pump. Medication infusion was initiated immediately after catheter insertion. The microcatheter was removed at the end of every treatment cycle.
Renegade hi flo
Manufactured by Boston Scientific
Sourced in United States
The Renegade Hi Flo is a medical device designed for use in interventional procedures. It serves as a delivery catheter, providing access and transportation of other devices or fluids to targeted areas within the body.
Automatically generated - may contain errors
Lab products found in correlation
6 protocols using renegade hi flo
1
Hepatic Artery Infusion Procedure
2
Middle Cerebral Artery Propofol Wada Test
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Middle cerebral artery (MCA) propofol Wada test protocol (26 (link)) and methylprednisolone injection prior to propofol (27 (link)) were adopted and performed by a veteran interventional neurosurgeon using microcatheter (Renegade HI FLO, Boston Scientific, Natick, Massachusetts, 01760-1537, USA). Vital signs were monitored non-invasively throughout the procedure. The detailed procedure was as follow. The ending point of microcatheter was placed at M1 segment of one side MCA after the distribution of intracarotid cerebral artery (ICA), and MCA was studied by cerebral angiography. Patients were instructed to raise and maintain their contralateral upper limb and to keep counting up aloud. The propofol dilute solution (propofol: 5%; glucose solution = 10 mg: 10 ml) was soon injected slowly through the catheter until effective events (contralateral limbs hemiplegia and interruption of counting numbers) were observed. Hand strength, sensitivity, and language function were evaluated throughout the test. Additional solution could be injected with the maximum dose of 15 ml in one side. The other side of the hemispheres was evaluated about 30 min after the procedure of one side. The aphasia side was defined as the Dominant Hemisphere (DH), whereas the other side was defined as the Contralateral Hemisphere (CH).
3
Combining TACE and MWA for HCC
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Before TACE-MWA treatment, all patients received a standardized pretreatment evaluation including history, laboratory, and imaging. All TACE and MWA were performed by five interventional radiologists with experience of more than 5 years. For TACE, a selective 5-F catheter (Yashiro type; Terumo Corporation) was introduced, and hepatic arterial angiography was performed to identify the tumor-feeding arteries. Then the tumor-feeding arteries were super-selective catheterized with a 2.7-F microcatheter (Renegade Hi Flo; Boston Scientific Corporation). The embolization emulsion was a mixture of 50 mg/m2 (link) of lobaplatin (Hainan Changan International Pharmaceutical Co., Ltd.), 10–40 mg of pirarubicin (Shenzhen Main Luck Pharmaceuticals Inc.) diluted in iodized oil (Lipoid ultra-fluid, Guerbet). MWA was performed within two weeks after TACE. MWA was performed with a commercially available system (ECO-100; ECO Microwave Electronic Institute) under CT guidance. A suitable route for puncture and ablation was designed. According to the size, number and anatomic location of the tumors, physicians chose the number of needles, the power (40–80W), and corresponding time (5–20 min) of ablation as well as the adjustable position of needles to eliminate the residual tumor. All ablations were conducted under intravenous moderate sedation and local anesthesia.
4
Transarterial Chemoembolization for Liver Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All TACE procedures were performed by two interventional radiologists with >10 years of experience. The right femoral artery was punctured using the Seldinger method, and the location, size, and blood supply of the tumor were confirmed intraoperatively using digital subtraction angiography. The microcatheter (Renegade Hi Flo, Boston Scientific Corp, USA) was super-selected to enter the tumor supply artery, and a mixture of iodinated oil (Guerbet, Paris, France (5 mL to 20 mL)), epirubicin ((Hisun Pfizer Pharmaceuticals, Fuyang, China) 20 mg to 30 mg), and oxaliplatin (Hengrui Medical, Suzhou, China (100 mg to 150 mg)) or 1 drug -loaded microsphere (Hengrui Medical, Suzhou, China (100 μm to 300 μm))+ 60 mg of famasin (Hisun Pfizer Pharmaceuticals, Fuyang, China) was injected into the selected tumor artery. Finally, 350 μm to 510 μm gelatin sponge particles (Alicon Pharmaceutical, Hangzhou, China) were bolstered to enhance the tumor supply to the artery. Patients were evaluated every 6 to 8 weeks by assessing alpha-fetoprotein (AFP) levels and tumor remnants using enhanced computed tomography (CT) or nuclear magnetic resonance imaging (MRI) for repeat TACE or surgery. To avoid the effect of the post-TACE embolic syndrome, AEs were recorded from one month after the procedure to the endpoint of follow-up.
5
Inducing Liver Cirrhosis in Oncopigs
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Liver cirrhosis was induced in 2 Oncopigs as previously described [51 (link)]. Procedures were undertaken following induction of general anesthesia. Briefly, with the Oncopig in a supine position, the groin area was sterilely prepped and draped. Femoral arterial access was gained via ultrasound guided vascular access, with placement of a 5 French vascular sheath (Pinnacle; Terumo, Somerset, NJ, USA). Using standard catheter and wire techniques, celiac arteriography was performed using a 5 French catheter (GLIDECATH; Terumo, Somerset, NJ, USA). A coaxial 3 French microcatheter (Renegade Hi-flo; Boston Scientific, Natick, MA, USA) was then advanced into the proper hepatic artery, and an emulsion of absolute ethanol and ethiodized oil (Lipiodol; Guerbet, Villepinte, France) (1:3 v/v dosed at 0.75 mL/kg) was slowly infused by manual injection into the hepatic arterial circulation over approximately 45-60 minutes. All devices were then removed, and hemostasis was obtained by direct compression at the vascular access site. Assessments were performed by a human pathologist according to the METAVIR system [52 (link)].
6
Transarterial Chemoembolization Procedure for Liver Tumors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Each patient underwent angiography via the femoral artery using Seldinger’s technique. Arteriography was routinely performed to collect information about the number, type and location of the tumors and feeding arteries, as well as the presence of vascular anatomic variations. After visualization of the arterial distribution and the portal system in the reflux phase for each individual patient, the most appropriate TACE procedure was selected. The feeding arteries to the lesion were catheterized as selectively as possible by using a highly flexible coaxial catheter (Renegade Hi Flo, Boston Scientific, Boston, MA, United States/Stride ASAHI INTECC, Seto, Japan). The chemoembolization procedure comprised injection of iodized oil (Lipiodol; Laboratoire Andre Guerbet, Aulnay-sous-Bois, France) mixed with 20–40 mg epirubicin hydrochloride (Main Luck Pharmaceutical, Shenzhen, China) as an emulsion into segmental or subsegmental tumor-feeding arteries. For patients with a hepatic arteriovenous fistula, sponge particles (Jinling, Nanjing, China) were used to block the fistula before the infusion of iodized oil.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!